Hansoh Pharmaceutical Group Company Ltd (3692.HK) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN KYG549581067
Hansoh Pharmaceutical Group Company Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 12.26 bn CNY | 15.03 bn CNY |
| Gross profit | 9.94 bn CNY | 14.45 bn CNY |
| EBIT | 3.59 bn CNY | 5.79 bn CNY |
| Net income | 4.37 bn CNY | 5.56 bn CNY |
| Diluted EPS – continuing operations | 0.65 CNY | 0.99 CNY |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hansoh Pharmaceutical Group Company Ltd
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.
More stocks
- Samsara Inc. (IOT)
- AXIA Energia SA (AXICY)
- Aker BP ASA (AKRBP.OL)
- AerCap Holdings NV (AER)
- Bandai Namco Holdings Inc (7832.T)
- Verisk Analytics (VRSK)
- EchoStar (ECHO)
- Suzuki Motor Corp (7269.T)
- Expeditors International (EXPD)
- Xylem Inc. (XYL)
- Hapag-Lloyd (HLAG.DE)
- ACS Actividades de Construccion y Servicios SA (ACS.MC)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.